Journals / Sağlık Bilimlerinde İleri Araştırmalar Dergisi / 2020 / Cilt: 3 - Sayı: S1

COVID-19 and Coagulopathy

COVID-19 ve Koagülopati

Pages
53–62
Publication Date
2020-05-15
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, the existing evidence, including studies on thrombotic complications, is very limited and derived primarily from small and retrospective analyses, and more strong and high quality new studies are required.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) is the causative pathogen of a new infectious disease, COVID-19.
📊
Key Findings & Data:The lungs are the target organ for COVID-19; acute lung injury can progress to respiratory failure, and multiorgan failure can also occur.
💡
Conclusion & Impact:However, the existing evidence, including studies on thrombotic complications, is very limited and derived primarily from small and retrospective analyses, and more strong and high quality new studies are required.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:COVID-19 · koagülopati · profilaksi

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) is the causative pathogen of a new infectious disease, COVID-19. The lungs are the target organ for COVID-19; acute lung injury can progress to respiratory failure, and multiorgan failure can also occur. COVID-19 may predispose to both venous and arterial thromboembolic disease due to coagulation activation caused by a combination of excessive inflammation, platelet activation, endothelial dysfunction, and stasis in blood flow. This review was prepared in the light of the current information available in the first months of the COVID-19 pandemic. However, the existing evidence, including studies on thrombotic complications, is very limited and derived primarily from small and retrospective analyses, and more strong and high quality new studies are required.

Özet

Ağır Akut Solunum Sendromu Coronavirus 2’nin (SARS-CoV2) etken patojen olduğu SARS-CoV2 enfeksiyonu (COVID-19) yeni bir enfeksiyon hastalığıdır. Akciğerler COVID-19 için hedef organdır; akut akciğer hasarı solunum yetmezliğine ilerleyebilir ve çoklu organ yetersizliği de gelişebilir. COVID-19; inflamasyon artışı, trombosit aktivasyonu, endotel disfonksiyonu ve kan akımında stazın etkisiyle hem venöz hem de arteriyel sistemde tromboz gelişimine neden olabilir. Bu derleme, COVID-19 pandemisinin ilk aylarındaki mevcut güncel bilgiler ışığı altında hazırlandı. Ancak, trombotik komplikasyonla ilgili çalışmalar da dahil mevcut kanıtlar çok sınırlıdır, başlıca az sayıda hastaların olduğu retrospektif analizlere dayalıdır, daha güçlü ve yüksek kalitede yeni çalışmalara ihtiyaç vardır.

🔖

Cite This Article

ÜNÜVAR, A. (2020). COVID-19 and Coagulopathy. Sağlık Bilimlerinde İleri Araştırmalar Dergisi, Cilt: 3 - Sayı: S1, 53–62. https://ajindex.com/articles/217118

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020 Feb 15;395:497-506. doi: 10.1016/ S0140-6736(20)30183-5
  2. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 2020 Apr 15. pii: S0735-1097(20)35008-7. doi: 10.1016/j.jacc.2020.04.031
  3. Cannegieter SC, Klok FA. COVID-19 associated coagulopathy and thromboembolic disease: Commentary on an interim expert guidance. Res Pract Thromb Haemost 2020 April 20. doi:10.1002/rth2.12350
  4. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020 Apr 27. pii: blood.2020006000. doi:10.1182/blood.2020006000
  5. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020;46(4):586-590. doi: 10.1007/s00134020-05985-9
  6. Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, Zhang Z. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost 2020 Apr 19. doi: 10.1111/ jth.14859
  7. Ranucci M, Ballotta A, Di Dedda U, Bayshnikova E, Dei Poli M, Resta M, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost 2020 Apr 17. doi: 10.1111/jth.14854
  8. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020 Mar28;395(10229):1054-1062. doi: 10.1016/ S0140-6736(20)30566-3
  9. Thachil J, Tang N, Gando S, Falanga A, Levi M, Clark C, Iba T. Laboratory haemostasis monitoring in COVID-19. J Thromb Haemost 2020 Apr 23. doi: 10.1111/jth.14866
  10. Thachil J. What do monitoring platelet counts in COVID-19 teach us? J Thromb Haemost 2020 Apr 28. doi: 10.1111/jth.14879
  11. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020;18(5):1023-1026. doi: 10.1111/jth.14810. Epub 2020 Apr 27
  12. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020 Apr;18(4):844-847. doi: 10.1111/j